424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
First tracked pre-IPO filing for this issuer.
Price $18.00 · 11,111,111 shares · Gross proceeds $199,999,998
Common · Exchange Nasdaq Global Market · Ticker CTY · Over-allotment 1,666,666 · Use of proceeds To fund clinical development of CITY-FXI, CITY-RBP4, CITY-TFR2, and advance the City Platform · Underwriters Goldman Sachs & Co. LLC, Jefferies, Stifel
City Therapeutics, Inc. reported significant increases in pretax losses and research and development expenses between 2024 and 2025, with a full valuation allowance on deferred tax assets due to cumulative losses and uncertainty about future profitability. The company operates as a single segment, deriving revenue from collaboration agreements with Bausch + Lomb and Biogen. Tax provisions remained zero, with no income tax payments made during the periods. The recent enactment of the OBBBA tax law had no material impact on financials but could affect future periods. The company expects cash runway through late 2028 with proceeds from this offering.
2026-10-16 · 0001104659-26-116636
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-10-15 · 9999999995-26-003256
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
2026-10-15 · 0001354457-26-000991
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
First tracked pre-IPO filing for this issuer.
2026-10-13 · 0001104659-26-115485
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
Price $18.00 · Range $17.00 to $19.00 · 9,722,222 shares
Common Stock · Exchange Nasdaq Global Market · Ticker CTY · Over-allotment 1,458,333 · Use of proceeds to fund clinical development of various programs, including Phase 1 and Phase 2 trials, and other research and development initiatives
City Therapeutics, Inc. disclosed detailed financial information in its S-1/A filing, emphasizing significant net operating loss (NOL) carryforwards and research and development (R&D) tax credit carryforwards. The company maintains a full valuation allowance against its deferred tax assets due to uncertainty about future profitability. Key financial highlights include $27.8 million and $58.5 million in pretax losses for 2024 and 2025, respectively, with no income tax provisions recognized. The company operates as a single reportable segment in the U.S., focusing on research collaborations with Bausch + Lomb and Biogen. The filing also notes potential limitations on NOL utilization under IRC Sections 382/383 and the impact of recent tax law changes like the OBBBA Act.
2026-10-09 · 0001104659-26-114815
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Stock · Exchange Nasdaq Global Market · Ticker CTY · Use of proceeds Clinical development of CITY-FXI, CITY-RBP4, and CITY-TFR2
City Therapeutics, Inc. is preparing for its IPO, as outlined in the S-1 filing, with a focus on its collaboration revenue from Bausch + Lomb and Biogen. The company reported a significant increase in collaboration revenue to $13.6 million for 2025, driven by new agreements and expanded research activities. However, it continues to operate at a loss, with research and development expenses rising to $58.4 million and general and administrative expenses to $15.1 million. The company emphasizes its reliance on external funding, noting that its current cash reserves, supplemented by the IPO proceeds, will only cover operations until a specific date. The filing highlights ongoing financial challenges, including the need for additional capital and the risks associated with its unproven product candidates.
2026-09-24 · 0001104659-26-110430
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
City Therapeutics, Inc. provides detailed disclosures on its accounting policies, including stock-based compensation, convertible preferred stock classification, and revenue recognition under ASC 606. The filing highlights recent adoption of accounting standards (ASU 2023-09 and ASU 2024-04) and emphasizes its financial losses for 2024 and 2025. The company's convertible preferred stock is classified as mezzanine equity due to redemption risks, and revenue recognition focuses on performance obligations and milestone payments.
2026-08-24 · 0001104659-26-099793
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
City Therapeutics, Inc. discloses its financial policies and accounting practices in its DRS filing, including the classification of convertible preferred stock as mezzanine equity, revenue recognition under ASC 606, and research and development expense accounting. The filing highlights the company's adherence to accounting standards, with specific attention to stock-based compensation, convertible debt, and income tax disclosures. Recent accounting updates, such as ASU 2023-09 and ASU 2024-04, are noted, reflecting compliance with evolving regulatory requirements.
2026-07-15 · 0001104659-26-083608